Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 73.00

From 52W high−11.79%

Volume2.45M

Market capCNY 7.28B

P/E (TTM)35.7x

P/S (TTM)6.9x

Div yield0.26%

Key dataSep 18, 2026

Open

CNY 73.00

From 52W high

−11.79%

Volume

2.45M

Market cap

CNY 7.28B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

32.3x

P/E (TTM)

35.7x

RSI (14)

64.4

MomentumView details →

1D Return

−1.53%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

35.7x

EV/EBITDA

32.3x

EV/Sales

7.1x

P/S (TTM)

6.9x

P/B (TTM)

5.9x

ProfitabilityView details →

Gross Margin

54.79%

Net Margin

16.40%

EBITDA Margin

21.95%

ROE (TTM)

15.55%

ROA (TTM)

8.47%

Asset Turnover

0.52x

GrowthView details →

Revenue YoY

+12.44%

EPS YoY

+46.53%

FCF YoY

—

Revenue CAGR 3Y

+21.79%

EPS CAGR 3Y

+9.93%

EBITDA YoY

—

MomentumView details →

1D Return

−1.53%

YTD Return

—

1Y Return

—

RSI (14)

64.4

vs 50D SMA

+14.68%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.46x

Current Ratio

1.79x

Quick Ratio

1.77x

Div Yield

0.26%

Div Rate

CNY 0.19

Div Growth 1Y

+14.72%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.19B

Net Income (TTM)

194.92M

Op. CF (TTM)

8.16M

Latest newsMore news →

Sunshine Lake Pharma's BTP0427 compound sustained-release capsules (Specifications I and II) received clinical trial approval from China's National Medical Products Administration for treating chronic heart failure with reduced ejection fraction.4d ago

Similar companies

鲁抗医药600789.SH 汇宇制药-W688553.SH 中恒集团600252.SH 上海谊众688091.SH 中牧股份600195.SH 太极集团600129.SH Find similar companies →

Latest newsMore news →

Sunshine Lake Pharma's BTP0427 compound sustained-release capsules (Specifications I and II) received clinical trial approval from China's National Medical Products Administration for treating chronic heart failure with reduced ejection fraction.4d ago